A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study.
COVID-19
SARS-CoV-2
azvudine
Journal
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
ISSN: 2198-3844
Titre abrégé: Adv Sci (Weinh)
Pays: Germany
ID NLM: 101664569
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
revised:
03
07
2020
received:
19
04
2020
entrez:
11
4
2022
pubmed:
1
10
2020
medline:
1
10
2020
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) has spread worldwide. To date, no specific drug for COVID-19 has been developed. Thus, this randomized, open-label, controlled clinical trial (ChiCTR2000029853) was performed in China. A total of 20 mild and common COVID-19 patients were enrolled and randomly assigned to receive azvudine and symptomatic treatment (FNC group), or standard antiviral and symptomatic treatment (control group). The mean times of the first nucleic acid negative conversion (NANC) of ten patients in the FNC group and ten patients in the control group are 2.60 (SD 0.97; range 1-4) d and 5.60 (SD 3.06; range 2-13) d, respectively (p = 0.008). The mean times of the first NANC of four newly diagnosed subjects in the FNC group and ten subjects in the control group are 2.50 (SD 1.00; range 2-4) d and 9.80 (SD 4.73; range 3-19) d, respectively (starting from the initial treatment) (p = 0.01). No adverse events occur in the FNC group, while three adverse events occur in the control group (p = 0.06). The preliminary results show that FNC treatment in the mild and common COVID-19 may shorten the NANC time versus standard antiviral treatment. Therefore, clinical trials of FNC treating COVID-19 with larger sample size are warranted.
Identifiants
pubmed: 35403380
doi: 10.1002/advs.202001435
pmc: PMC7404576
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2001435Subventions
Organisme : Henan Genuine Biotech Co., Ltd.
ID : 201100311500
Organisme : National S&T Major Project of China
ID : 2018ZX10301201-008
Organisme : National Key Research and Development Program of China
ID : 2018YFC2000500
Organisme : National Natural Science Foundation of China
ID : U1804283
Organisme : Henan Province Science and Technology Project
ID : 202102310055
Informations de copyright
© 2020 The Authors. Published by Wiley-VCH GmbH.
Références
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
J Med Chem. 2009 May 14;52(9):2971-8
pubmed: 19341305
J Virol. 2020 Apr 16;94(9):
pubmed: 32075935
JAMA. 2020 Feb 25;323(8):707-708
pubmed: 31971553
Adv Sci (Weinh). 2020 Oct;7(19):e2001435
pubmed: 35403380
Adv Virus Res. 2011;81:85-164
pubmed: 22094080
Allergy. 2020 Jul;75(7):1564-1581
pubmed: 32396996
Nat Rev Drug Discov. 2013 Jun;12(6):447-64
pubmed: 23722347
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
PLoS One. 2015 Dec 17;10(12):e0142287
pubmed: 26678487
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Antivir Ther. 2012;17(8):1593-9
pubmed: 22910281
PLoS Med. 2017 May 16;14(5):e1002299
pubmed: 28510573
BMJ. 2020 May 14;369:m1849
pubmed: 32409561
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464